| Autor: |
Dickson K; Sally McDonnell Barksdale Honors College, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS. Kennedy Dickson is studying Forensic Chemistry at the University of Mississippi and is a Sally McDonnell Barksdale Honors College Scholar. She studies marijuana therapeutics under Dr. Willett in the Department of BioMolecular Sciences at the University of Mississippi. She has begun the law school admissions process for Fall 2020 and plans to pursue a joint J.D. and Master of Bioethics degree. This paper is based on her Sally McDonnell Barksdale Honors College Thesis for which she was one of three national recipients of the National Collegiate Honors Council Portz Scholarship., Janasie C; The National Sea Grant Law Center, University of Mississippi School of Law. Catherine Janasie is Senior Research Counsel with the National Sea Grant Law Center at the University of Mississippi School of Law, where she provides legal and policy analysis to organizations and government entities on ocean, coastal, and natural resources issues and teaches environmental law classes, including Agricultural Law and Natural Resources Law., Willett KL; Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS. Kristine L. Willett is Chair and Professor of Pharmacology and Environmental Toxicology in the Department of BioMolecular Sciences. Her research is supported by the National Institute on Drug Abuse to study potential adverse outcomes of developmental exposure to cannabis constituents. She teaches graduate and undergraduate toxicology and environmental health courses. |
| Jazyk: |
angličtina |
| Zdroj: |
Arizona journal of environmental law & policy [Arizona J Environ Law Policy] 2019 Fall; Vol. 10 (20), pp. 132-150. |
| Abstrakt: |
Marijuana is the most commonly used, cultivated, and trafficked illicit drug worldwide. In the United States, the use and acceptance of marijuana is evolving rapidly as indicated by the volume of new state cannabis legislation. However, marijuana is still a Schedule I drug under the federal Controlled Substances Act (CSA). Further complicating the matter, the 2018 Farm Bill removed hemp from the list of controlled substances under the CSA, resulting in a market flooded with cannabidiol (CBD) products that have not been approved by the Food and Drug Administration (FDA). Many of the changes in state laws have occurred without significant input from medical or scientific communities. The status of marijuana and, until recently, hemp as Schedule I drugs under the CSA creates numerous restrictions which ultimately impact the industry as a whole. The central issues facing marijuana legality in the U.S. are: convoluted state and federal law, adverse health effects of cannabis use, research restrictions that produce knowledge gaps, and inconsistency between the U.S. Food and Drug Administration (FDA) and the U.S. Environmental Protection Agency (EPA) regulations. Marijuana policy must evolve to protect and inform both the general public and individuals involved in the cannabis industry. Potential reform options include: federal exemptions following state compliance, rescheduling marijuana, or complete removal from the CSA. The most vital step in the federal legalization process needs to be less restrictive research opportunities for marijuana. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
